SCHEMBL5467445

SCHEMBL5467445

CC(C)(C)OC(=O)N1CCN(c2ccc(NC(=O)Nc3nc(C(C)(C)C)cs3)cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
SMN1; SMN2 Q16637 4/20 0.56
ALDH1A1 P00352 3/20 0.56
NPC1 O15118 2/20 0.56
MAPK1 P28482 2/20 0.56
POLB P06746 1/20 0.56
RAB9A P51151 1/20 0.56
NAMPT P43490 1/20 0.53
MAPT P10636 3/20 0.53
TSHR P16473 1/20 0.53
FLT3 P36888 1/20 0.47
LMNA P02545 2/20 0.47
GPR119 Q8TDV5 2/20 0.47
ESR2 Q92731 1/20 0.47
NR2F2 P24468 1/20 0.47
HTT P42858 1/20 0.47
JAK2 O60674 2/20 0.45
JAK3 P52333 2/20 0.45
BRAF P15056 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5459850 0.88 RAB9A (0.64) MEN1KMT2ASMN1; SMN2ALDH1A1NPC1
SCHEMBL5455957 0.87 WNT3A (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1NPC1
SCHEMBL5469374 0.87 NAMPT (0.52) MEN1KMT2ASMN1; SMN2ALDH1A1NPC1
SCHEMBL5463418 0.86 NAMPT (0.51) MEN1KMT2ASMN1; SMN2ALDH1A1NPC1
SCHEMBL5459405 0.83 RAB9A (0.62) MEN1KMT2ASMN1; SMN2ALDH1A1NPC1
SCHEMBL5466915 0.81 SMN1; SMN2 (0.56) MEN1KMT2ASMN1; SMN2ALDH1A1NPC1
SCHEMBL5460938 0.81 NAMPT (0.64) MEN1KMT2ASMN1; SMN2ALDH1A1NPC1
SCHEMBL5463529 0.79 KMT2A (0.62) MEN1KMT2ASMN1; SMN2ALDH1A1NPC1
SCHEMBL2957603 0.79 MAPK14 (0.60) MEN1KMT2ASMN1; SMN2NPC1NAMPT
SCHEMBL13853617 0.79 NAMPT (0.66) MEN1KMT2ASMN1; SMN2ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070249620-A1 Urea Derivative SANKYO COMPANY, LIMITED (JP) 2007-10-25 US disclosed
EP-1764360-A1 UREA DERIVATIVE Sankyo Company, Limited (JP) 2007-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070249620-A1 Urea Derivative UGP2, SLC14A1, DGAT1 MEN1 1828/4885KMT2A 1350/4885SMN1; SMN2 4424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.